JP2011529964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529964A5 JP2011529964A5 JP2011522114A JP2011522114A JP2011529964A5 JP 2011529964 A5 JP2011529964 A5 JP 2011529964A5 JP 2011522114 A JP2011522114 A JP 2011522114A JP 2011522114 A JP2011522114 A JP 2011522114A JP 2011529964 A5 JP2011529964 A5 JP 2011529964A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- alkynyl
- heteroaryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 40
- -1 cycloalkenylalkyl Chemical group 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 230000000813 microbial effect Effects 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 108010003026 UDP-3-O-acyl-N-acetylglucosamine deacetylase Proteins 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- QUJXIMWUJGTUEG-CLKUPZDLSA-N 2-[2-[[[(2s,6s,9e,13s)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid Chemical compound C([C@H]1CC(=O)N[C@@H](CC/C=C/CC[C@@H](C(N1)=O)N)C(=O)NCC=1C(=CC=CC=1)CC(O)=O)C1=CC=C(O)C=C1 QUJXIMWUJGTUEG-CLKUPZDLSA-N 0.000 claims description 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 2
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 0 CC(C)(*(C(NO)O)NC(CCCN(CC*)C(C=C1)=CCC1=*(CC1)CCC1N1CCNCC1)=O)O Chemical compound CC(C)(*(C(NO)O)NC(CCCN(CC*)C(C=C1)=CCC1=*(CC1)CCC1N1CCNCC1)=O)O 0.000 description 3
- RTOGLJIVQSFYJY-UHFFFAOYSA-N C(CC1)CCN1C(CC1)C=CC1C#CC(CC1)C=CC1N1CCNCC1 Chemical compound C(CC1)CCN1C(CC1)C=CC1C#CC(CC1)C=CC1N1CCNCC1 RTOGLJIVQSFYJY-UHFFFAOYSA-N 0.000 description 1
- ZUGMNMDCFQYIBT-UHFFFAOYSA-N CC(C)(CNC(N(CC1)CCN1C(CC1)=CC=C1C1=CCCCC1)=O)C1CC1 Chemical compound CC(C)(CNC(N(CC1)CCN1C(CC1)=CC=C1C1=CCCCC1)=O)C1CC1 ZUGMNMDCFQYIBT-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8598208P | 2008-08-04 | 2008-08-04 | |
| US61/085,982 | 2008-08-04 | ||
| PCT/US2009/051898 WO2010017060A1 (en) | 2008-08-04 | 2009-07-28 | Urea derivatives as antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529964A JP2011529964A (ja) | 2011-12-15 |
| JP2011529964A5 true JP2011529964A5 (https=) | 2012-08-30 |
Family
ID=41171285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522114A Pending JP2011529964A (ja) | 2008-08-04 | 2009-07-28 | 抗菌剤としての尿素誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110212080A1 (https=) |
| EP (1) | EP2315746A1 (https=) |
| JP (1) | JP2011529964A (https=) |
| AU (1) | AU2009279949A1 (https=) |
| CA (1) | CA2732045A1 (https=) |
| WO (1) | WO2010017060A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5539864B2 (ja) | 2007-06-12 | 2014-07-02 | アカオゲン，インコーポレーテッド | 抗菌剤 |
| WO2010032147A2 (en) | 2008-09-19 | 2010-03-25 | Pfizer Inc. | Hydroxamic acid derivatives useful as antibacterial agents |
| DK2512474T3 (en) | 2009-12-16 | 2014-12-01 | Pfizer | N-linked hydroxamic acid derivatives which can be used as antibacterial agents |
| CA2796750C (en) | 2010-04-20 | 2017-09-19 | Taisho Pharmaceutical Co., Ltd. | Novel hydroxamic acid derivative |
| WO2012031298A2 (en) | 2010-09-03 | 2012-03-08 | Duke University | Ethynylbenzene derivatives |
| MA34963B1 (fr) * | 2011-03-07 | 2014-03-01 | Pfizer | Derives de fluoro-pyridinone utiles en tant qu'agents antibacteriens |
| CA2830866A1 (en) | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| WO2012137094A1 (en) | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Isoxazole derivatives useful as antibacterial agents |
| JP6006609B2 (ja) * | 2011-10-19 | 2016-10-12 | 大正製薬株式会社 | 新規なヒドロキサム酸誘導体を含有する医薬 |
| WO2013170165A1 (en) | 2012-05-10 | 2013-11-14 | Achaogen, Inc. | Antibacterial agents |
| WO2014165075A1 (en) | 2013-03-12 | 2014-10-09 | Achaogen, Inc. | Antibacterial agents |
| JP6259814B2 (ja) | 2013-03-15 | 2018-01-10 | 富山化学工業株式会社 | 新規なヒドロキサム酸誘導体またはその塩 |
| US10189786B2 (en) | 2013-08-16 | 2019-01-29 | Duke University | Antibacterial compounds |
| CA2921427A1 (en) | 2013-08-16 | 2015-02-19 | Duke University | Substituted hydroxamic acid compounds |
| US9908851B2 (en) * | 2013-08-16 | 2018-03-06 | Duke University | 2-piperidinyl substituted N,3-dihydroxybutanamides |
| RU2017112319A (ru) | 2014-09-12 | 2018-10-12 | Тояма Кемикал Ко., Лтд. | Новая фармацевтическая композиция, содержащая производное гидроксамовой кислоты или его соль |
| BR112017004796A2 (pt) | 2014-09-12 | 2017-12-12 | Toyama Chemical Co Ltd | método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| TW201803847A (zh) | 2016-06-23 | 2018-02-01 | 美商爾察禎有限公司 | 抗菌劑 |
| US12359222B2 (en) | 2016-11-03 | 2025-07-15 | Temple University-Of The Commonwealth System Of Higher Education | DNA plasmids for the fast generation of homologous recombination vectors for cell line development |
| WO2019154412A1 (zh) * | 2018-02-10 | 2019-08-15 | 山东亨利医药科技有限责任公司 | 作为抗菌素的化合物 |
| CN115232130B (zh) * | 2021-04-22 | 2024-01-12 | 山东大学 | 一种apn和akt双靶点抑制剂及其制备方法和应用 |
| WO2023011573A1 (zh) * | 2021-08-05 | 2023-02-09 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925659A (en) * | 1996-05-07 | 1999-07-20 | Merck & Co., Inc. | Antibacterial agents |
| US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
| ES2283589T3 (es) * | 2001-06-15 | 2007-11-01 | Vicuron Pharmaceuticals, Inc. | Compuestos biciclicos de pirrolidina. |
| CA2851462A1 (en) * | 2003-01-08 | 2004-07-29 | University Of Washington | Antibacterial agents |
| JP5117382B2 (ja) * | 2006-05-31 | 2013-01-16 | 第一三共株式会社 | ７員環化合物の製造方法 |
-
2009
- 2009-07-28 EP EP09790866A patent/EP2315746A1/en not_active Withdrawn
- 2009-07-28 CA CA2732045A patent/CA2732045A1/en not_active Abandoned
- 2009-07-28 WO PCT/US2009/051898 patent/WO2010017060A1/en not_active Ceased
- 2009-07-28 AU AU2009279949A patent/AU2009279949A1/en not_active Abandoned
- 2009-07-28 US US13/057,505 patent/US20110212080A1/en not_active Abandoned
- 2009-07-28 JP JP2011522114A patent/JP2011529964A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529964A5 (https=) | ||
| JP2011525927A5 (https=) | ||
| KR102061137B1 (ko) | 금속효소 억제제 화합물 | |
| JP2020526561A5 (https=) | ||
| JP5535941B2 (ja) | 殺菌性アミド | |
| EP3119755B1 (en) | Antifungal compound process | |
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| EA036098B1 (ru) | Способ получения противогрибковых соединений | |
| EP3119764B1 (en) | Antifungal compound process | |
| JP2011520969A5 (https=) | ||
| CA2683696A1 (en) | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity | |
| UA78039C2 (en) | Amidinyl phenyl compounds, fungicide compositions and a method for controlling plants diseases | |
| JP2017533968A5 (https=) | ||
| JP2010506854A5 (https=) | ||
| JP2020517707A5 (https=) | ||
| CN102421756A (zh) | 杀真菌的吡唑化合物 | |
| JP2014520809A5 (https=) | ||
| JP2013528652A5 (https=) | ||
| JP2020527173A5 (https=) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2016508492A5 (https=) | ||
| JP2017509644A (ja) | 抗真菌化合物の調製方法 | |
| JP2015536997A5 (https=) | ||
| TW200738698A (en) | Organic compounds | |
| CN110225781A (zh) | 噻唑衍生物及其应用 |